Blood product acquired HIV infection in children.

F. Desposito, George McSherry, J. M. Oleske

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The medical community needs to ensure safety of blood and blood products. Blood bankers have instituted rigid criteria for exclusion of potential donors in high risk categories. Institution of HIV testing would appear to make blood products safer although the complete elimination of HIV contaminated blood and blood products may not be possible. The ELISA test is excellent for screening but misses approximately 1 in 200 (0.5%) HIV infected donors. Donor-screened, heat-treated factor VIII products appear to be quite effective in protecting the hemophilia population. However, we must continue to search for methodologies and techniques which will further guarantee blood product safety. The following methodologies have been suggested and warrant strong consideration: Vigilance in exclusion of potential high risk donors. Newer methodologies for retrovirus screening including the use of other surrogate markers. Institution of screening for HTLV-I and other retroviruses with attention to population surveillance for newer agents. Institution of cleaner methods of extracting specific blood components by monoclonal antibody techniques and DNA methodologies. For hemophiliacs, development of recombinant DNA products which by-pass the need for plasma derived clotting factors. It is predicted that such products should become available for use in about two years. In the interim, all clotting factors used should be donor-screened and virus-inactivated (by heat treatment, detergent washing and/or other newer methodologies). For the blood recipient, programs allowing for self donation prior to elective surgery and designated donors should be implemented. Although such programs may be logistically difficult, they should be given high priority.(ABSTRACT TRUNCATED AT 250 WORDS)

Original languageEnglish (US)
Pages (from-to)341-345
Number of pages5
JournalPediatric Annals
Volume17
Issue number5
DOIs
StatePublished - Jan 1 1988

Fingerprint

HIV Infections
Tissue Donors
Blood Safety
Blood Coagulation Factors
HIV
Retroviridae
Hot Temperature
Population Surveillance
Donor Selection
Human T-lymphotropic virus 1
Recombinant DNA
Factor VIII
Hemophilia A
Detergents
Biomarkers
Enzyme-Linked Immunosorbent Assay
Monoclonal Antibodies
Viruses
DNA
Population

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health

Cite this

Desposito, F. ; McSherry, George ; Oleske, J. M. / Blood product acquired HIV infection in children. In: Pediatric Annals. 1988 ; Vol. 17, No. 5. pp. 341-345.
@article{46b186b3155742109e9de2b6efacc599,
title = "Blood product acquired HIV infection in children.",
abstract = "The medical community needs to ensure safety of blood and blood products. Blood bankers have instituted rigid criteria for exclusion of potential donors in high risk categories. Institution of HIV testing would appear to make blood products safer although the complete elimination of HIV contaminated blood and blood products may not be possible. The ELISA test is excellent for screening but misses approximately 1 in 200 (0.5{\%}) HIV infected donors. Donor-screened, heat-treated factor VIII products appear to be quite effective in protecting the hemophilia population. However, we must continue to search for methodologies and techniques which will further guarantee blood product safety. The following methodologies have been suggested and warrant strong consideration: Vigilance in exclusion of potential high risk donors. Newer methodologies for retrovirus screening including the use of other surrogate markers. Institution of screening for HTLV-I and other retroviruses with attention to population surveillance for newer agents. Institution of cleaner methods of extracting specific blood components by monoclonal antibody techniques and DNA methodologies. For hemophiliacs, development of recombinant DNA products which by-pass the need for plasma derived clotting factors. It is predicted that such products should become available for use in about two years. In the interim, all clotting factors used should be donor-screened and virus-inactivated (by heat treatment, detergent washing and/or other newer methodologies). For the blood recipient, programs allowing for self donation prior to elective surgery and designated donors should be implemented. Although such programs may be logistically difficult, they should be given high priority.(ABSTRACT TRUNCATED AT 250 WORDS)",
author = "F. Desposito and George McSherry and Oleske, {J. M.}",
year = "1988",
month = "1",
day = "1",
doi = "10.3928/0090-4481-19880501-08",
language = "English (US)",
volume = "17",
pages = "341--345",
journal = "Pediatric Annals",
issn = "0090-4481",
publisher = "Slack Incorporated",
number = "5",

}

Blood product acquired HIV infection in children. / Desposito, F.; McSherry, George; Oleske, J. M.

In: Pediatric Annals, Vol. 17, No. 5, 01.01.1988, p. 341-345.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Blood product acquired HIV infection in children.

AU - Desposito, F.

AU - McSherry, George

AU - Oleske, J. M.

PY - 1988/1/1

Y1 - 1988/1/1

N2 - The medical community needs to ensure safety of blood and blood products. Blood bankers have instituted rigid criteria for exclusion of potential donors in high risk categories. Institution of HIV testing would appear to make blood products safer although the complete elimination of HIV contaminated blood and blood products may not be possible. The ELISA test is excellent for screening but misses approximately 1 in 200 (0.5%) HIV infected donors. Donor-screened, heat-treated factor VIII products appear to be quite effective in protecting the hemophilia population. However, we must continue to search for methodologies and techniques which will further guarantee blood product safety. The following methodologies have been suggested and warrant strong consideration: Vigilance in exclusion of potential high risk donors. Newer methodologies for retrovirus screening including the use of other surrogate markers. Institution of screening for HTLV-I and other retroviruses with attention to population surveillance for newer agents. Institution of cleaner methods of extracting specific blood components by monoclonal antibody techniques and DNA methodologies. For hemophiliacs, development of recombinant DNA products which by-pass the need for plasma derived clotting factors. It is predicted that such products should become available for use in about two years. In the interim, all clotting factors used should be donor-screened and virus-inactivated (by heat treatment, detergent washing and/or other newer methodologies). For the blood recipient, programs allowing for self donation prior to elective surgery and designated donors should be implemented. Although such programs may be logistically difficult, they should be given high priority.(ABSTRACT TRUNCATED AT 250 WORDS)

AB - The medical community needs to ensure safety of blood and blood products. Blood bankers have instituted rigid criteria for exclusion of potential donors in high risk categories. Institution of HIV testing would appear to make blood products safer although the complete elimination of HIV contaminated blood and blood products may not be possible. The ELISA test is excellent for screening but misses approximately 1 in 200 (0.5%) HIV infected donors. Donor-screened, heat-treated factor VIII products appear to be quite effective in protecting the hemophilia population. However, we must continue to search for methodologies and techniques which will further guarantee blood product safety. The following methodologies have been suggested and warrant strong consideration: Vigilance in exclusion of potential high risk donors. Newer methodologies for retrovirus screening including the use of other surrogate markers. Institution of screening for HTLV-I and other retroviruses with attention to population surveillance for newer agents. Institution of cleaner methods of extracting specific blood components by monoclonal antibody techniques and DNA methodologies. For hemophiliacs, development of recombinant DNA products which by-pass the need for plasma derived clotting factors. It is predicted that such products should become available for use in about two years. In the interim, all clotting factors used should be donor-screened and virus-inactivated (by heat treatment, detergent washing and/or other newer methodologies). For the blood recipient, programs allowing for self donation prior to elective surgery and designated donors should be implemented. Although such programs may be logistically difficult, they should be given high priority.(ABSTRACT TRUNCATED AT 250 WORDS)

UR - http://www.scopus.com/inward/record.url?scp=0024003714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024003714&partnerID=8YFLogxK

U2 - 10.3928/0090-4481-19880501-08

DO - 10.3928/0090-4481-19880501-08

M3 - Article

VL - 17

SP - 341

EP - 345

JO - Pediatric Annals

JF - Pediatric Annals

SN - 0090-4481

IS - 5

ER -